Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of ...
Everyday Health on MSN

Obstructive vs. nonobstructive hypertrophic cardiomyopathy (HCM): What your diagnosis means for treatment and lifestyle

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...
Seeking Alpha

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and ...
MedCity News

Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure

Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO ...
Nasdaq

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...
Nasdaq

Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics

Cytokinetics, Incorporated announced findings from two analyses of the SEQUOIA-HCM trial that studied the effects of aficamten on patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM ...